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Abstract
Background Alternative administration methods are emerging as a key area of research to improve clinical efficacy of anti-
biotics and address concerns regarding multi-drug resistance. Extended intermittent infusions or continuous infusions of 
antibiotics exhibiting time-dependent kill characteristics may be favourable in critically ill septic patients, but more evidence 
is needed to determine best practice. Objective To find out whether any common practice exists for intravenous antibiotic 
administration in critical care units across UK NHS Trusts, and identify factors influencing the adoption of extended or 
continuous infusions. Setting UK hospitals. Method UK critical care pharmacists were invited to participate in a survey on 
behalf of all 240 critical care units via a UK Clinical Pharmacy Association message board. The survey focused on admin-
istration practices for 22 antibacterial agents. Main outcome measure Antibiotic administration method. Results Responses 
were received covering 64 units, a response rate of 26.2%. Common, but not uniform administration methods were apparent 
for 17/22 antibiotics. Four antibiotics (piperacillin/tazobactam, doripenem, meropenem and vancomycin) were more likely 
to be administered as continuous or extended-intermittent infusions. Choice of administration method was especially influ-
enced by altered pk/pd properties in sepsis or severe burns patients, or by the presence of organisms requiring high minimal 
inhibitory concentrations. Conclusion Unlicensed alternative practices of antibiotic administration are widespread but only 
weak evidence exists of any patient benefit, such as reduced length of stay in critical care, and none showing improvement in 
mortality. Further research is needed to determine whether extended infusion methods offer clinically meaningful advantages 
over shorter licenced administration methods in patients in critical care units.
Keywords Antibiotic administration · Clinical outcome · Critical care · Critical care pharmacist · Sepsis · Therapeutic drug 
monitoring · United Kingdom
Impacts on practice
• Administration method of antibiotics in practice often 
does not strictly follow guidance provided by the sum-
mary of product characteristics for each antibiotic, mean-
ing practitioners take responsibility for deviating from 
the licensed method.
• The apparent lack of “standard” practice for the adminis-
tration of antibiotics demonstrates that there is a need for 
evidence synthesis and evidence-based guidance to try 
to improve a number of important clinical and efficiency 
outcomes in critical care.
Introduction
Antibiotic selection in UK hospitals is largely guided by 
local policy and guidelines that have been developed for 
common organisms or infection sites and with resistance and 
susceptibility patterns in mind. Antibiotic policies generally 
state the antibiotic to be prescribed, along with the dose, 
frequency and route of administration but rarely specify a 
method of administration, e.g. how quickly a bolus should 
be given or the time over which an infusion should run. 
Given the escalating global concern regarding multi-drug 
resistant organisms, alternative methods of administration 
and dosing strategies are becoming a key area of research 
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interest to improve clinical efficacy of available antibiotics. 
A growing body of published evidence [1, 2] shows that in 
the critically ill septic patient extended intermittent infusions 
(EIIs) or continuous infusions (CIs) of antibiotics exhibiting 
time-dependent kill characteristics may be favoured because 
of their pharmacokinetic/pharmacodynamic (pk/pd) proper-
ties, but more evidence is needed to determine best practice.
In the intensive care setting infection and related sepsis is 
the leading cause of death with a mortality rate of up to 60% 
[3]. Although clinical guidance exists for some aspects of 
antibacterial therapy such as timing (e.g. in “sepsis 6”) and 
which classes of antibacterial should be used [4, 5], at the 
time of the survey no guidance existed specifying methods 
of intravenous antibacterial administration, although this has 
since changed [5].
Two recent clinical trials [1, 6] have shown an increase 
in clinical cure rates with continuous infusions, whereas 
another trial [7] failed to show improvement, but whether 
alternative administration methods change the risk of 
mortality in critically ill patients remains unknown. The 
ADMIN-ICU survey [8] of antibiotic dosing and monitor-
ing in ICUs showed very diverse practices in administration 
of selected antibacterial agents from responding sites across 
53 countries, and concluded that further research to develop 
best practice guidelines is required.
Aim of the study
To find out whether any ‘usual’ (common) practice exists 
for intravenous antibiotic administration in critical care units 
across UK NHS Trusts, and identify factors influencing the 
adoption of extended or continuous infusions of antibiotics.
Ethics approval
Ethics approval for this study was obtained from the Liver-
pool John Moores University Research Ethics Committee 
(13/SPS/044). Research was conducted in accordance with 
the Declaration of Helsinki and UK/EU and institutional 
standards. Informed consent was obtained from all individ-
ual participants included in the study.
Method
Study design
A survey was designed to collect data on: 1. pertinent 
demographic information of the responding pharmacists 
and CCUs (specialty, seniority, grade, experience and CCU 
microbiologist cover); 2. the usual method of intravenous 
administration of each of 22 antimicrobial agents; 3. any 
alternative methods being used to administer intravenous 
antibiotics; 4. the driving forces for selection of certain intra-
venous administration practices.
The survey was distributed using the ‘Bristol Online Sur-
veys’ tool and responses were collected using a variety of 
methods, including drop-down menu options and radio but-
tons with some free-text options, which were later grouped 
by themes. Choice of the topics and questions for inclusion/
exclusion in the survey was guided by personal experience 
of the subject matter and the published literature to identify 
themes and relevant antibiotics.
Participant anonymity was maintained as far as possi-
ble during data collection, and details from individual NHS 
Trusts are not shown as the aim of the study was to look at 
UK trends not individual Trust practice. The survey was 
piloted with a small number of critical care pharmacists via 
a secure message board, and amendments made according 
to their reponses and suggestions.
Participants (UK hospital critical care pharmacists) were 
invited to complete the survey via the UKCPA CCG mes-
sage board, during an 8-week period between October and 
December 2013. Two follow-up reminder messages were 
posted 2 and 6 weeks after the initial invitation. There were 
244 critical care units (CCUs) in the UK at the time of the 
survey and 600 pharmacists registered with the UKCPA 
CCG message board. A list of CCUs was obtained from the 
Intensive Care National Audit & Research Centre (ICNARC) 
and the Scottish Intensive Care Societies Audit Group 
(SICSAG) and all units listed with a pharmacist member 
of the UKCPA CCG were invited to participate. Duplicate 
responses from individual Trusts were removed by using 
only the response given by the most senior pharmacist, on 
the basis that they would potentially be more knowledgeable 
about the practices than junior pharmacists.
For the purposes of this study, “usual practice” was 
defined as existing when an antibiotic was administered by 
the same method on greater than 50% of responding CCUs. 
Data values were exported into  Microsoft®  Excel® (for  Mac® 
2011, v. 14.6.2) and statistical analysis was performed using 
 IBM®  SPSS® Statistics 21.0. Demographic data were pre-
pared as distribution frequencies and percentages, as were 
data comparing antibiotics, the method of administration, 
the stated factors influencing practice and the rate of TDM. 
The Chi squared test was used to assess differences between 
groups. Statistical significance level was set at α = 0.05.
Results
The questionnaire asked for the pharmacist responding to 
do so for all the CCUs that they worked on, as some cover 
multiple CCUs within the same NHS Trust. In total, 54 
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pharmacists responded on behalf of 64 CCUs, a response 
rate of 26.2%.
90.6% (58/64) of responding CCUs were from England, 5 
from Scotland and 1 from Northern Ireland, and at least one 
unit responded from the majority of Critical Care Networks 
(CCNs)/regions in the UK as defined by ICNARC/SICSAG. 
Table 1 shows a summary of the characteristics of respond-
ing pharmacists and their associated CCUs.
Administration and monitoring practices
The usual administration method of 22 antibacterial agents 
was ascertained for each CCU (Table 2). Of these, only 4 
antibiotics were given by a single administration method 
across all responding CCUs (ticarcillin/clavulanic acid, imi-
penem/cilastatin, tigecycline, and ciprofloxacin). However, 
frequency analysis showed that 17/22 antibiotics had a single 
preferred method of administration used in greater than 50% 
of the responding CCUs. Four antibiotics were administered 
on at least 20% of CCUs by EII or CI: piperacillin/tazobac-
tam, doripenem, meropenem and vancomycin. Doripenem 
was reportedly only used in 3 of the responding CCUs, and 
ampicillin in only 2, so were not included in further analy-
ses. Piperacillin/tazobactam and meropenem were adminis-
tered as EIIs in 22.2% and 20.3% respectively of responding 
CCUs, and vancomycin by CI in 48.4% of CCUs. Thera-
peutic drug monitoring, which serves to influence dosing 
and administration methods, was reportedly done for only 
glycopeptide and aminoglycoside agents (100% of CCUs) 
but no other agents.
Factors affecting choice of administration method 
including alternative dosing methods
A number of factors affected the adoption of EII or CI for 
each antibiotic. Higher pharmacist grade (p = 0.028), greater 
Table 1  Characteristics of 
responding critical care units
*Burns/trauma × 1, complex respiratory × 1
n (%)
Country England 58 (90.6)
Wales 0 (0)
Scotland 5 (7.8)
Northern Ireland 1 (1.6)




Size of CCU < 10 beds 14 (21.9)
10–20 beds 31 (48.4)
> 20 beds 12 (18.8)
Not known 7 (10.9)
CCU pharmacist grade (agenda for change band) 7 6 (9.4)
8a 31 (48.4)
8b–9 27 (42.2)
Pharmacist years experience in CCU < 1 2 (3.1)
1–5 11 (17.2)
6–10 19 (29.7)
> 10 32 (50.0)
CCU pharmacist cover Never 0 (0)
Rarely/ad hoc 1 (1.6)
Weekdays 52 (81.3)
Weekdays and Saturdays 0 (0)
Everyday 11 (17.2)
Pharmacist attending consultant-led CCU ward round Yes 47 (73.4)
No 17 (26.6)
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pharmacist cover (p < 0.001) and greater microbiologist 
input (p = 0.031) were associated with the adoption of EIIs 
as the usual method of administration of piperacillin/tazo-
bactam rather than the method stated in the summary of 
product characteristics (SPC). Practice also varied between 
critical care networks/regions, with some adopting predomi-
nantly EII usage and others using either bolus or short infu-
sion. The only factor associated with EII administration of 
meropenem was greater pharmacist cover (p < 0.001). Adop-
tion of local policy for vancomycin administration by CI 
was associated with the presence of the pharmacist on the 
consultant-led ward round (p = 0.03).
In 7.8% (5/64) CCUs, EII or CI administration methods 
were also chosen for patients on renal replacement therapy 
and in 15.6% (10/64) the administration method was influ-
enced by other patient factors including fluid restriction 
(2/64), endocarditis (1/64), septic shock (4/64), major burns 
(1/64) and identification of Pseudomonas spp. (2/64). The 
most commonly stated reason for using alternative admin-
istration methods in 48% (31/64) CCUs for using EII/CI 
was “Evidence Based—pk/pd properties”, with “Evidence 
based—improved outcomes” also registering highly in 
40.6% (26/64) responses. “Cost” was stated in only 3.7% 
(2/64).
9.4% (6/64) of responders believed the total daily dose 
of vancomycin differed when using EII/CI: on 2 CCUs they 
thought they would use a lower overall dose whereas another 
4 responders thought they would use a bigger dose. No CCU 
used EII with the specific aim of reducing the total daily 
dose of antibacterial required.
Discussion
We found that there was a great deal of variability in 
administration practices across responding sites in the UK, 
although some patterns emerged leading us to identify usual 
administration practice (greater than 50% of responses) for 
17 out of the 22 intravenous antibiotics surveyed, which all 
followed the method stated in the SPC. The findings from 
our UK survey square with those reported from the world-
wide ADMIN-ICU study [8], though we sought informa-
tion specifically from critical-care pharmacists over a larger 
group of antibacterial agents.
Table 2  Reported antibacterial 
administration method
B, bolus injection, i.e. over 5 min or less; S/B, short infusion as per the SPC or bolus injection (dependent 
on dose); S/SPC, short infusion as per the SPC; EII, extended intermittent infusion, i.e. the drug is infused 
over a period that is longer than that suggested in the SPC; CI, Continuous infusion, i.e. the drug is infused 
continuously for the duration of the treatment course; N/A, agent not used
Usual method of administration per CCU, n (%)
B S/B S/SPC EII CI N/A No. of CCUs
Benzylpenicillin 30 (48.4) 6 (9.7) 22 (35.5) 4 (6.4) 2 62
Flucloxacillin 30 46.9) 8 (12.5) 22 (34.4) 4 (6.2) 64
Amoxicillin 38 (65.5) 8 (13.8) 12 (20.7) 6 58
Ampicillin 1 (50) 1 (50) 62 2
Co-amoxiclav 40 (67.8) 13 (22) 6 (10.2) 5 59
Piperacillin/tazobactam 17 (27) 32 (50.8) 14 (22.2) 1 63
Ticarcillin/clavulanic acid 10 (100) 54 10
Cefotaxime 20 (60.6) 2 (6.1) 11 (33.3) 31 33
Ceftazidime 20 (40.8) 1 (2) 20 (40.8) 8 (16.4) 15 49
Ceftriaxone 22 (36.7) 1 (1.7) 33 (55) 4 (6.6) 4 60
Cefuroxime 24 (61.5) 11 (28.2) 4 (10.3) 25 39
Doripenem 2 (66.7) 1 (33.3) 61 3
Ertapenem 5 (13.2) 33 (86.8) 26 38
Imipenem/cilastatin 5 (100) 59 5
Meropenem 29 (45.3) 4 (6.3) 18 (28.1) 13 (20.3) 64
Tigecycline 38 (100) 26 38
Clarithromycin 63 (98.4) 1 (1.6) 64
Clindamycin 62 (96.8) 2 (3.2) 64
Vancomycin 32 (50.8) 31 (49.2) 1 63
Teicoplanin 34 (57.6) 25 (42.4) 5 59
Linezolid 60 (96.7) 2 (1.7) 2 62
Ciprofloxacin 64 (100) 64
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Definite trends in choice of antibiotic were found to exist 
within some classes of antibacterial agents. Of the broad-
spectrum penicillins, amoxicillin alone and in combination 
with clavulanic acid (co-amoxiclav) were used by most units 
whereas ampicillin was rarely used. Piperacillin/tazobactam 
was the clear favourite out of the anti-pseudomonal peni-
cillins and meropenem was the most commonly prescribed 
carbapenem.
There is often a logical theoretical rationale for extending 
the length of time over which some antibiotics are admin-
istered in light of pk/pd studies, but there is currently little 
published in the way of supportive clinical evidence for this 
which demonstrates any clear improvement in the risk of 
further patient morbidity or mortality. We identified three 
antibacterials which were administered by EII or CI as the 
usual method of administration (piperacillin/tazobactam, 
meropenem and vancomycin), which are often prescribed 
to treat severe infection and/or sepsis.
Comparison of CI or EII methods over standard 
administration
In light of the lack of definitive evidence to show that CIs 
offer an improvement on licensed methods of administration 
it is interesting to note that approximately half of responding 
CCUs (49.2%) have adopted CIs as their standard practice. 
Our findings point to pharmacist input having the biggest 
influence on the choice of alternative methods of administra-
tion—particularly of vancomycin, piperacillin/tazobactam 
and meropenem. On the other hand, patient orientated fac-
tors affected choice of administration in only a small number 
of responses, such as renal replacement therapy or endocar-
ditis. Therapeutic drug monitoring (TDM) was used to guide 
therapy in all CCUs using vancomycin regardless of method 
of administration in line with standard UK practice [9]. It is 
possible that CIs are favourable for TDM practice allowing 
greater ease of monitoring.
A prospective multicentre RCT which compared efficacy, 
safety and cost effectiveness of vancomycin CIs compared 
with standard therapy [10], showed a shorter time to target 
concentrations in the CI arm but microbiological or clini-
cal superiority of CIs was not demonstrated. However, CIs 
showed a 23% cost saving for a 10 day course compared 
to standard dosing, revealing CI to be a potentially favour-
able administration option when scaled up. Another study 
[11] showed that the incidence of nephrotoxicity increases 
with vancomycin trough concentrations in patients receiv-
ing standard dosing, with around 5% incidence when ini-
tial trough concentrations is < 10 mg/L and as high as 33% 
if trough concentration is > 20 mg/L. It is unknown if this 
effect is caused directly by high trough concentrations, or 
the associated higher peak or total exposure over the dosing 
interval, but it is nonetheless of clinical interest as we found 
that many CI protocols which aim to eliminate peaks and 
troughs target vancomycin concentrations of 15–25 mg/L. 
However, the best available evidence to date indicates there 
is no difference in the incidence of vancomycin nephrotoxic-
ity between standard and CI methods of administration [12].
Meropenem and piperacillin/tazobactam are generally 
administered every 8 h and have half-lives of approximately 
1 h in patients with normal renal function, leaving extended 
between-dose periods of time below minimum inhibitory 
concentration (MIC). This is considered to be a contributing 
factor in treatment failure and the development of resist-
ance to these agents [13]. Bigger and/or more frequent doses 
or the use of EIIs or CIs have been suggested as ways of 
improving clinical outcome and reducing resistance [14, 15].
Meropenem and piperacillin/tazobactam are both cur-
rently licensed in the UK to be administered as short infu-
sions with a suggested duration of 30 min, and meropenem 
is also licensed for administration as a bolus injection over 
5 min. Advice to give bolus piperacillin/tazobactam was 
removed from the UK SPC in 2011 to harmonise with the 
rest of the EU where it is licensed only for short infusion 
[16]. The pk/pd benefits of CIs and EIIs to these agents has 
been reviewed [17, 18] and recent RCTs have shown there 
may be a patient benefit in these alternative administration 
methods [6, 19] and although the BLING II study [7] did 
not show any benefit to patient outcomes from continuous 
infusions, the findings of a 2018 meta-analysis [20] support 
the use of continuous infusions of piperacillin-tazobactam 
in critically ill patients to reduce mortality and improve the 
rate of clinical cure.
Factors influencing use of alternative dosing 
methods
Where EIIs or CIs were not the “usual” method of adminis-
tration in a given CCU, some respondents stated that under 
certain circumstances they would recommend or use these 
methods. The reasons stated could be split into two catego-
ries. The first would be classed as patients with conditions 
that are perceived to have significantly altered the pk/pd 
parameters such as septic shock and major burn injury. Both 
of these conditions cause an increase in volume of distribu-
tion and an increase in renal clearance of water soluble, low 
protein bound drugs such as the β lactams being discussed 
[21]. Multiple studies have shown drug plasma levels to 
be altered in these patient groups [22–24] and others have 
shown that EIIs or CIs lead to a more favourable pk/pd pro-
file [25]. It is therefore logical that prescribers may target 
the patients who are likely to gain the most from these prac-
tices. The second area is in targeting organisms that have the 
highest MICs and therefore require high concentrations of 
antimicrobial at the target site: 2 CCUs used EIIs of pipera-
cillin/tazobactam and meropenem solely for the treatment of 
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Pseudomonas spp. which have a high MIC and are noted for 
high treatment failure rates and development of resistance 
[26]. Many studies that have investigated EIIs of β-lactams 
used their ability to maintain levels 4-times greater than the 
MIC of Pseudomonas spp. as the target measure [27, 28]. 
Again, this supports treatment of Pseudomonas spp. with 
EIIs.
Factors influencing choice of administration method
Almost half of respondents stated that a major influencing 
factor was the evidence-base supporting the pk/pd benefits 
of EIIs and CIs, but a large proportion of the same respond-
ents also stated that they believed the published evidence 
demonstrated improved patient outcomes. We found a lack 
of evidence to corroborate this in the literature in contrast 
to the respondents’ opinions, which may indicate that some 
pharmacists have only a superficial grasp of the evidence. 13 
respondents stated reduced vancomycin toxicity as a driving 
force for choice. Respondents reported that CIs of vancomy-
cin are generally more convenient—easier for the nursing 
staff to manage, simpler dose adjustments, timing of TDM 
less important so interpretation of the plasma level is also 
easier and therefore under/over- dosing easier to prevent. 
Interestingly, only 2 respondents stated cost saving as a driv-
ing force. Cost improvement plans and means of saving on 
drug budgets are necessarily towards the forefront of most 
pharmacists’ minds during every working day in practice 
and given that many published studies, particularly from the 
USA, report that lower total daily doses are required when 
EIIs or CIs are used, it is perhaps surprising more respond-
ents didn’t rate this as a more important consideration. For 
example, Grant et al. [29] investigated using a loading dose 
of 4.5 g piperacillin/tazobactam followed by a CI of 9 g per 
day rather than the licensed dose of 4.5 g three or four times 
daily, finding similar clinical efficacy but a treatment course 
cost of $399.38 for CIs vs. $523.49 for licensed practices 
where shorter infusion times are employed.
The role of therapeutic drug monitoring
TDM is universally carried out for aminoglycosides (e.g. 
gentamicin) and glycopeptides (e.g. vancomycin). In the 
UK, TDM is a key part of standard care for these antibiotics 
because of their nephrotoxic and ototoxic nature and narrow 
therapeutic drug index, and more recently with vancomy-
cin to ensure serum trough levels are maintained between 
15 and 20 mg/L, or that 24-h AUC:MIC ratio > 400. Given 
the ease of calculation of AUC for continuous infusions of 
vancomycin, CI offers a real advantage in improving patient 
outcomes. Many centres outside the UK do not incorporate 
any TDM into antibiotic therapy as a matter of course, with 
20% of respondents stating they did not monitor gentamicin 
serum concentration at all, and a further 19% only did so 
if the patient was in renal failure [8]. The DALI study [30] 
demonstrated that TDM is especially important in personal-
ising β-lactam antibiotic dosing and administration in criti-
cally ill patients, to prevent adverse patient outcomes arising 
from inadequate dosing.
Limitations of the study
The response rate for the survey is relatively low despite 
attempts to follow up potential participants, and responses 
are largely confined to English CCUs. Although this limits 
the impact of the findings, the responses do provide a useful 
picture of the administration practice of antibiotics in UK 
CCUs, especially in revealing where there is lack of consist-
ency or “standard” across UK NHS Trusts.
Conclusion
‘Usual’ intravenous administration practices exist for most 
antibiotics used in UK CCUs, with deviation from the SPC 
mainly limited to three antibacterial agents with pk/pd pro-
files that particularly lend themselves to extended infusions 
and to minimise perceived risk. CCUs tended to follow 
licensed/SPC methods of administration and where there 
was no usual practice this was because there was a split 
in responses across multiple licensed methods of admin-
istration. Further research is needed to determine whether 
extended infusion methods offer clinically meaningful 
advantages over shorter licenced administration methods in 
CCU patients.
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